As part of an ongoing series of “Expert Perspectives”, Dr. Leon Henderson-MacLennan, Medical Advisor to inDemic Foundation and inThought Research, discusses the role of thromboembolic disease in COVID-19, and its implications for developmental therapeutics. Dr. Leon Henderson-MacLennan describes the rationale for conducting randomized, placebo-controlled trials on anticoagulants and anticomplement agents for COVID-19 associated thromboembolic disease, and highlights several agents and mechanisms of action to watch closely.
In the first of an ongoing series of “Expert Perspectives” with members of inDemic Foundation’s scientific advisory board, we discuss data from EMPACTA, a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy and safety of Roche’s Actemra (tocilizumab) in hospitalized patients with COVID-19 pneumonia (NCT04372186). Actemra is one of several IL-6 inhibitors that’s been evaluated for patients with COVID-19. At the time of this writing, data from EMPACTA has not been published in a peer-reviewed journal, but some of its key findings have been released by Roche/Genentech.
This Q&A is with Bob Dickson, MD, associate professor of pulmonary and critical care medicine at University of Michigan, and Hrishikesh Kulkarni, MD, MSCI, assistant professor of pulmonary and critical care medicine at Washington University in St. Louis.